Medical Oncology

premenopausal

Questions discussed in this category

Would you consider anthracycline based neoadjuvant therapy for ER negative, HER2 positive inflammatory breast cancer in a premenopausal female given the subset not adequately represented in non-anthracycline regimen trials?

3 Answers available

Papers discussed in this category

Lancet Oncol., 2018 Nov 06

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.

Related Topics in Medical Oncology